Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
4 "Sung Hye Kong"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Response
Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes Metab J. 2019;43(6):913-914.   Published online December 26, 2019
DOI: https://doi.org/10.4093/dmj.2019.0149
  • 3,060 View
  • 40 Download
  • 1 Web of Science
PDFPubReader   
Short Communication
Clinical Diabetes & Therapeutics
Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes Metab J. 2019;43(5):711-717.   Published online March 20, 2019
DOI: https://doi.org/10.4093/dmj.2018.0208
  • 3,711 View
  • 58 Download
  • 10 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   
Background

The study aimed to evaluate the effects of dapagliflozin and metformin on vascular endothelial function and renal injury markers.

Methods

This prospective, randomized, open-label, crossover study included drug-naïve patients with type 2 diabetes mellitus, who were randomized to receive 8 weeks of initial treatment using metformin or dapagliflozin and crossed over for another 8 weeks of treatment after a 1-week washout period. Systemic endothelial function was evaluated via the reactive hyperemic index (RHI).

Results

The 22 participants included 10 males (45.5%) and had a median age of 58 years. The RHI values were not significantly changed during both 8-week treatment periods and there was no significant difference between the treatments. Relative to the metformin group, 8 weeks of dapagliflozin treatment produced significantly higher median N-acetyl-beta-D-glucosaminidase levels (10.0 ng/mL [interquartile range (IQR), 6.8 to 12.1 ng/mL] vs. 5.6 ng/mL [IQR, 3.8 to 8.0 ng/mL], P=0.013). Only the dapagliflozin group exhibited improved homeostatic model assessment of insulin resistance and body weight, while serum ketone and β-hydroxybutyrate levels increased.

Conclusion

Dapagliflozin treatment did not affect systemic endothelial function or renal injury markers except N-acetyl-beta-D-glucosaminidase.

Citations

Citations to this article as recorded by  
  • Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
    Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Elena Mele, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele,
    Pharmacological Research.2023; 188: 106659.     CrossRef
  • Novel use of structural equation modelling to examine diet and metabolic traits associated with microvascular endothelial dysfunction in middle-aged Chinese males: a cross-sectional study
    Rujia Miao, Renhe Yu, Hui Zhou, Lei Liu, Ting Peng, Jiangang Wang
    BMJ Open.2023; 13(9): e073357.     CrossRef
  • Endothelial Dysfunction and Heart Failure with Preserved Ejection Fraction—An Updated Review of the Literature
    Mariarosaria De Luca, Giulia Crisci, Giuseppe Armentaro, Sebastiano Cicco, Giovanni Talerico, Emanuele Bobbio, Lorena Lanzafame, Christopher G. Green, Abbie G. McLellan, Radek Debiec, Paolo Caferra, Roberto Scicali, Antonio Cannatà, Muhammad Zubair Israr,
    Life.2023; 14(1): 30.     CrossRef
  • Renoprotection by Dapagliflozin in a Non-Diabetic Model of Cardiorenal Syndrome
    Konrad Urbanek, Donato Cappetta, Gabriella Bellocchio, Maria Antonietta Coppola, Paola Imbrici, Marialucia Telesca, Maria Donniacuo, Maria Antonietta Riemma, Eleonora Cianflone, Silvio Naviglio, Elena Conte, Giulia Maria Camerino, Marco Mele, Mariarosaria
    SSRN Electronic Journal .2022;[Epub]     CrossRef
  • Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
    Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
    Nutrition & Diabetes.2021;[Epub]     CrossRef
  • Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
    Gloria M. Gager, Dirk von Lewinski, Harald Sourij, Bernd Jilma, Ceren Eyileten, Krzysztof Filipiak, Martin Hülsmann, Jacek Kubica, Marek Postula, Jolanta M. Siller-Matula
    Biomedicine & Pharmacotherapy.2021; 143: 112169.     CrossRef
  • Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction
    Marie-Sophie L.Y. de Koning, B. Daan Westenbrink, Solmaz Assa, Erwin Garcia, Margery A. Connelly, Dirk J. van Veldhuisen, Robin P.F. Dullaart, Erik Lipsic, Pim van der Harst
    Journal of the American College of Cardiology.2021; 78(14): 1421.     CrossRef
  • Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium‐glucose co‐transporter‐2 inhibitors
    Dimitrios Patoulias, Christodoulos Papadopoulos, Konstantinos Stavropoulos, Ioanna Zografou, Michael Doumas, Asterios Karagiannis
    The Journal of Clinical Hypertension.2020; 22(4): 562.     CrossRef
  • Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes
    Yehuda Handelsman
    Advances in Therapy.2019; 36(10): 2567.     CrossRef
  • Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
    Dimitrios Patoulias, Michael Doumas
    Diabetes & Metabolism Journal.2019; 43(6): 906.     CrossRef
  • Response: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-Naïve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711–7)
    Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
    Diabetes & Metabolism Journal.2019; 43(6): 913.     CrossRef
Response
Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes Metab J. 2017;41(2):152-153.   Published online April 14, 2017
DOI: https://doi.org/10.4093/dmj.2017.41.2.152
  • 3,142 View
  • 35 Download
  • 1 Web of Science
  • 1 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Letter: Comparison of the Efficacy of Rosuvastatin Monotherapy 20 mg with Rosuvastatin 5 mg and Ezetimibe 10 mg Combination Therapy on Lipid Parameters in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2019;43:582–9)
    Tae Seo Sohn
    Diabetes & Metabolism Journal.2019; 43(6): 909.     CrossRef
Original Article
Clinical Care/Education
Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus
Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
Diabetes Metab J. 2017;41(1):23-30.   Published online December 16, 2016
DOI: https://doi.org/10.4093/dmj.2017.41.1.23
  • 4,669 View
  • 85 Download
  • 10 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   
Background

There has been evidences of ethnic differences in the low density lipoprotein cholesterol (LDL-C) lowering effect of statin. We aimed to evaluate the efficacy of moderate-intensity statins in the treatment of dyslipidemia among Korean patients with type 2 diabetes mellitus (T2DM).

Methods

We analyzed a retrospective cohort that consisted of Korean patients with T2DM aged 40 to 75 years who had been prescribed any of the moderate-intensity statins (atorvastatin 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, or pravastatin 40 mg). Among them, only patients with baseline lipid profiles before starting statin treatment were selected, and changes in their lipid profiles before and 6 months after statin therapy were analyzed.

Results

Following the first 6 months of therapy, the overall LDL-C reduction was −47.4% (interquartile range, −56.6% to −34.1%). In total, 92.1% of the participants achieved an LDL-C level of <100 mg/dL, 38.3% had a 30% to 50% reduction in their LDL-C levels, and 42.3% had a reduction in their LDL-C levels greater than 50%. The response rates of each drug for achieving a LDL-C level <100 mg/dL were 81.7%, 93.1%, 95.0%, 95.0%, 96.5%, and 91.7% for treatment with atorvastatin doses of 10 or 20 mg, rosuvastatin 5 or 10 mg, pitavastatin 2 mg, and pravastatin 40 mg, respectively.

Conclusion

In conclusion, the use of moderate-intensity statins reduced LDL-C levels less than 100 mg/dL in most of the Korean patients studied with T2DM. The efficacies of those statins were higher than expected in about 42% of Korean patients with T2DM.

Citations

Citations to this article as recorded by  
  • Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH)
    Yanyan Han, Ling Ren, Xiang Fei, Jingjing Wang, Tao Chen, Jun Guo, Qi Wang
    Atherosclerosis.2024; 391: 117471.     CrossRef
  • Impact of Plasma Exposure of Statins and Their Metabolites With Major Adverse Cardiovascular Events in Chinese Patients With Coronary Artery Disease
    Xiao-hong Zhou, Li-yun Cai, Wei-Hua Lai, Xue Bai, Yi-bin Liu, Qian Zhu, Guo-dong He, Ji-Yan Chen, Min Huang, Zhi-ling Zhou, Shi-long Zhong
    Frontiers in Pharmacology.2020;[Epub]     CrossRef
  • Efficacy and Safety of High-Dose Atorvastatin in Moderate-to-High Cardiovascular Risk Postmenopausal Korean Women with Dyslipidemia
    Jaecheol Moon, Soyeon Yoo, Gwanpyo Koh, Kyung-Wan Min, Hyun Ho Shin
    Journal of Lipid and Atherosclerosis.2020; 9(1): 162.     CrossRef
  • Effects of lowest-dose vs. highest-dose pitavastatin on coronary neointimal hyperplasia at 12-month follow-up in type 2 diabetic patients with non-ST elevation acute coronary syndrome: an optical coherence tomography analysis
    Jung Wook Lim, Han Saem Jeong, Soon Jun Hong, Hyo Jeong Kim, Young Chan Kim, Bong Gyun Kang, Su Min Jeon, Jae Young Cho, Seung Hoon Lee, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu
    Heart and Vessels.2019; 34(1): 62.     CrossRef
  • Effect of Statin Therapy on Outcomes of Patients With Acute Ischemic Stroke and Atrial Fibrillation
    Kang‐Ho Choi, Woo‐Keun Seo, Man‐Seok Park, Joon‐Tae Kim, Jong‐Won Chung, Oh Young Bang, Gyeong‐Moon Kim, Tae‐Jin Song, Bum Joon Kim, Sung Hyuk Heo, Jin‐Man Jung, Kyung‐Mi Oh, Chi Kyung Kim, Sungwook Yu, Kwang‐Yeol Park, Jeong‐Min Kim, Jong‐Ho Park, Jay Ch
    Journal of the American Heart Association.2019;[Epub]     CrossRef
  • Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis
    Mahn-Won Park, Gyung-Min Park, Seungbong Han, Yujin Yang, Yong-Giun Kim, Jae-Hyung Roh, Hyun Woo Park, Jon Suh, Young-Rak Cho, Ki-Bum Won, Soe Hee Ann, Shin-Jae Kim, Dae-Won Kim, Sung Ho Her, Sang-Gon Lee, George C.M. Siontis
    PLOS ONE.2018; 13(12): e0207889.     CrossRef
  • Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
    Jae-Han Jeon
    Diabetes & Metabolism Journal.2017; 41(2): 150.     CrossRef
  • Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30)
    Sung Hye Kong, Bo Kyung Koo, Min Kyong Moon
    Diabetes & Metabolism Journal.2017; 41(2): 152.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal
Close layer